NCT06913647View on ClinicalTrials.gov

Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
ESRDCKD (Chronic Kidney Disease) Stage 5D
Interventions
DRUG

Canagliflozin 300 MG

Canagliflozin 300 mg once daily

Trial Locations (1)

Unknown

Research Institute-McGill University Health Center, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER